which is used to treat rheumatoid arthritis. The acquisition of Dice Therapeutics will further strengthen Eli Lilly's position in the field of immunology and expand its range of treatment options for patients with immune-related diseases.
In addition to its existing drugs, Eli Lilly will now have access to Dice Therapeutics' innovative technology platform, which has the potential to revolutionize the development of oral therapeutic drugs for autoimmune diseases. This platform utilizes a unique approach that targets specific immune cells and modulates their activity, providing a more targeted and effective treatment option for patients.
The $2.4 billion deal reflects Eli Lilly's commitment to investing in research and development to address unmet medical needs in the field of immunology. By acquiring Dice Therapeutics, Eli Lilly aims to accelerate the development of new therapies and bring them to market faster, ultimately improving the lives of patients suffering from immune-related diseases.
Overall, the acquisition of Dice Therapeutics is a strategic move for Eli Lilly to strengthen its position in the immunology market and expand its treatment portfolio. With the addition of Dice Therapeutics' technology platform, Eli Lilly will be able to develop innovative oral therapeutic drugs that have the potential to transform the way autoimmune diseases are treated. This deal highlights Eli Lilly's dedication to advancing medical science and providing better treatment options for patients in need.